Cohance Lifesciences sits in the path of drugmakers shifting work away from China and growing interest in newer cancer treatments, but the upside depends on turning a strong pipeline into real production without stumbles. Delays in scaling new facilities and clearing quality checks, plus pressure from low-cost competitors in specialty chemicals, could keep profits from improving as quickly as investors expect.Read more
Cohance Lifesciences is pushing into newer drug-making services like antibody drug conjugates and oligonucleotides, and a wave of late-stage customer programs could turn today’s lumpy demand into steadier growth over time. The catch is recent guidance changes and customer delays, so the upside depends on whether these higher-value projects actually ramp as planned.Read more
Cohance Lifesciences is trying to grow by buying new capabilities and expanding into complex drug-making services that big global pharma companies increasingly rely on. The upside comes from stronger demand and new facilities, but a lot depends on smooth deal integration and whether new projects arrive when expected.Read more
No trending discussion available.
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.
